bispecific antibodies targeting CD45 and 90Y-DOTA (Fred Hutchinson Cancer Research Center/University of Washington School of Medicine/Massachusetts Institute of Technology)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Namebispecific antibodies targeting CD45 and 90Y-DOTA (Fred Hutchinson Cancer Research Center/University of Washington School of Medicine/Massachusetts Institute of Technology)
Drug Alias Name30F11-Fc-C825 (Fred Hutchinson Cancer Research Center/University of Washington School of Medicine/Massachusetts Institute of Technology)BC8-Fc-C825 (Fred Hutchinson Cancer Research Center/University of Washington School of Medicine/Massachusetts Institute of Technology)BC8-Fc-C82530F11-Fc-C825
ClassificationRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionLeukocyte common antigen inhibitors
TargetsLeukocyte common antigen
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWashington UniversityFred Hutchinson Cancer Research CenterMassachusetts Institute Of Technology
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A